about
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.Current advances and challenges in HIV-1 vaccines.Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for deliverySafety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States.Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa.P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research.First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine.Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.Trial-related discrimination in HIV vaccine clinical trials.P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccineP15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?P15-18. Behavioral and social science in HIV vaccine clinical research: workshop recommendationsHigh‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsSocial impact of preventive HIV vaccine clinical trial participation: A model of prevention, assessment and interventionHIV vaccines: Biological and clinical considerationsSafety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesAntigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialAntibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
P50
Q36158727-3C58AF85-E9C2-4A0E-95DF-362A977C5DC1Q36362287-EE996487-DDCD-45A2-ABEE-6B34EEEB1DB4Q36415785-AC413450-C093-4E1D-8F9B-CE5301D2149FQ37070349-49E679F0-5125-4B5C-B1AC-237C773B0054Q37216571-47F02C57-3DC7-4791-89A0-5455A8FC3683Q37617853-A0F7A7DF-7256-4DDC-B848-FEB3E61BBF5DQ40184158-0D5F244E-AAB1-4963-8632-9C9998CC386EQ40373124-482BA1B0-ECB7-4DDE-9921-F3EAC39346BAQ44536209-AEDA3530-D5DF-452C-9863-BCA9314AA28EQ45833382-1689F2F8-BA97-4950-BD63-86EF76B3DE83Q46889673-D66BF454-2D12-4B7F-962F-6F167AFB6A88Q46988701-D762517F-E956-45AD-A7F3-04D57D405057Q47845658-74E4B823-AFCF-477C-9E3B-3BC46BD4A3CFQ51065183-70280699-9DB9-446E-BC20-F1D6E0B5FCBEQ57990163-82154CB3-FD8A-4CF2-A79C-96E94C4F1DD8Q57990198-39DAFD3F-C550-478E-B37B-8D4F98038B5DQ59249061-E8039514-2834-40D7-8D0C-47E5EC11332EQ59650903-F338E2EE-9241-4562-B782-D06A1FC4D04CQ60920345-A0FA669C-E6B8-4DA7-9E03-A31552802A58Q60920348-2FFD92B0-9622-4B9C-82C8-15999F5D26BDQ89857234-24E4F86B-B8F0-4829-B5CF-621C319DC310Q91360476-AA9644E3-EB59-48F1-89C7-2FE6FC234BACQ95649524-CF0A5254-BA88-4D01-A3B8-C94BEA3EF669
P50
description
researcher, ORCID id # 0000-0001-8163-0714
@en
wetenschapper
@nl
name
Mary Allen
@ast
Mary Allen
@en
Mary Allen
@es
Mary Allen
@nl
type
label
Mary Allen
@ast
Mary Allen
@en
Mary Allen
@es
Mary Allen
@nl
prefLabel
Mary Allen
@ast
Mary Allen
@en
Mary Allen
@es
Mary Allen
@nl
P106
P1153
8737351600
P21
P31
P496
0000-0001-8163-0714